GlobeNewswire - Industry News on Biotechnology

Equillium Announces Closing of $30 Million Registered Direct Offering

Fri, 05 Feb 2021 22:36 GMT

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15^th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.? ?

Pacific Biosciences Grants Equity Incentive Award to New Employee

Fri, 05 Feb 2021 22:00 GMT

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).

argenx announces closing of global offering

Fri, 05 Feb 2021 21:01 GMT

Regulated information

Amendment: Trading by management and close relations of management

Fri, 05 Feb 2021 19:17 GMT

Please read the full announcement in?PDF

TG Therapeutics Announces FDA Accelerated Approval of UKONIQ? (umbralisib)

Fri, 05 Feb 2021 18:55 GMT

UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

Valneva - Déclaration d’actions et de droits de vote – Janvier 2021

Fri, 05 Feb 2021 17:00 GMT

VALNEVA

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

Fri, 05 Feb 2021 16:30 GMT

VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced that the Company’s common shares (the “Shares”) are expected to commence trading on the Canadian Securities Exchange (the “CSE”) on Monday, February 8, 2021, under the ticker symbol “DRUG.”

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium?

Fri, 05 Feb 2021 14:00 GMT

– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –

– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

Fri, 05 Feb 2021 13:30 GMT

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Fri, 05 Feb 2021 13:00 GMT

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

Fri, 05 Feb 2021 13:00 GMT

Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints

Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints

Silence Therapeutics plc Announces $45 Million Private Placement

Fri, 05 Feb 2021 12:00 GMT

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Fri, 05 Feb 2021 12:00 GMT

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at 2:00 p.m. ET. The conference will be held in a virtual meeting format.

Orchard Therapeutics Announces $150 Million Strategic Financing

Fri, 05 Feb 2021 12:00 GMT

Strengthened Financial Position Supports Execution into the First Half of 2023

Strengthened Financial Position Supports Execution into the First Half of 2023

Vor Biopharma Announces Pricing of Initial Public Offering

Fri, 05 Feb 2021 11:33 GMT

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately $176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

Trading by management and close relations of management

Fri, 05 Feb 2021 07:13 GMT

Please read the full announcement in?PDF

Tiziana Life Sciences plc ("Tiziana" or the "Company") -?Appointment of Director

Fri, 05 Feb 2021 07:00 GMT

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020

Fri, 05 Feb 2021 07:00 GMT

Message from the CEO

Infant Bacterial Therapeutics AB (publ), (IBT) Del?rsrapport 1 januari – 31 december 2020

Fri, 05 Feb 2021 07:00 GMT

VD Kommenterar

Santhera Completes Capital Increase for Financing Arrangements

Fri, 05 Feb 2021 06:00 GMT

Pratteln, Switzerland, February?5, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 1,600,000 treasury shares. The number of shares recorded in the commercial register has been increased to 21,029,696 shares.